News & Press Releases
Filter by:
Mintz Continues Expansion of Private Equity Practice and New York Office with Addition of Andrew Hulsh as Member
April 17, 2023
Mintz is pleased to announce that Andrew Hulsh, a leading private equity attorney with a particular focus on renewable energy and life sciences, has joined the firm as a Member in its New York office.
Mintz has once again been named a recipient of the National Legal Aid & Defender Association (NLADA)’s Beacon of Justice Award. This year, the award was given to law firms that demonstrated their “efforts to address issues related to LGBTQ+ rights and/or gender-based equity issues that intersect with racial equity.”
Mintz Member Natashia Tidwell Appointed By Governor Maura Healey To Judicial Nominating Commission
April 13, 2023
BOSTON – Mintz is pleased to announce that Member Natashia Tidwell has been appointed by Governor Maura Healey to the new Judicial Nominating Commission (JNC), a 27-member panel that will pre-screen applicants for open judgeships and other court positions.
Mintz Continues To Expand Leading Life Sciences And Private Equity Capabilities In Toronto
April 12, 2023
TORONTO – Mintz continues to grow in Canada and extend its market-leading life sciences and private equity capabilities. The addition of Partners Matthew Atkey and Brad Tartick, Special Counsel Bernard Kwasniewski and Of Counsel Matthew Imrie, will bolster Mintz’s premier capital markets, M&A, funds, and employment and pensions-focused practices.
WASHINGTON, D.C. – Mintz’s Private Equity Co-Chair, Matthew T. Simpson is one of a group of experts arranged by the Public International Law & Policy Group (PILPG) to develop a series of tools and resources to assist with potential future ceasefire negotiations between Ukraine and Russia.
Mintz Advises Underwriters of Viking’s $287.5 Million Public Offering of Common Stock
April 10, 2023
NEW YORK – Mintz represented the syndicate of underwriters led by William Blair & Company, L.L.C., in the public offering of 17,242,000 shares of common stock of Viking Therapeutics, Inc. (“Viking”) (Nasdaq: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, at an initial offering price of $14.50 per share.